Anne Dixon, MD
Pulmonary Disease · Burlington, VTNPI 1164431847
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,800 of the $4,025 with a category attached, or 69.6%. Eli Lilly accounts for 69.6% of it on its own, with 4 other manufacturers making up the rest. 2024 is the largest year on record at $2,800, 2.4 times the $1,170 reported in 2019.
Across 6 payments — averaging $670.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- F. Hoffmann-la Roche AG$669
- Boehringer Ingelheim International GmbH$501
- CSL Behring$36
- United Therapeutics Corporation$19
Across 27 payments — averaging $20,676 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$505K
- Novo Nordisk AS$46K
- F. Hoffmann-la Roche AG$6K
- Sanofi-aventis U.S. LLC$863
What the payments were for
- Consulting fees$2,80070%
- Speaking & faculty fees$1,17029%
- Education$551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $2,800 |
| F. Hoffmann-la Roche AG | 1 | $669 |
| Boehringer Ingelheim International GmbH | 1 | $501 |
| CSL Behring | 2 | $36 |
| United Therapeutics Corporation | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,025 in reported general payments places this provider in the 85th percentile of 25 pulmonary disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 19 | $73,553 |
| Fasenra PenBenralizumab | 12 | $68,824 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,559 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $7,092 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $5,459 |
| Mycophenolate Mofetil | 18 | $3,573 |
| Azithromycin | 16 | $744 |
| Roflumilast | 16 | $451 |
| Prednisone | 42 | $328 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $45 |
| Famotidine | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Burlington
- Charles KinseyBurlington$34K
- Emily DucombBurlington$10K
- Daniel WeissBurlington$3K
- Christopher YuroskoBurlington$2K
- Ena GuptaBurlington$2K
- Marta KokoszynskaBurlington$1K
- Suman MajumdarBurlington$786
- Jessica BadlamBurlington$642
- Prema MenonBurlington$18
- Garth GarrisonBurlington$18
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.